Cadence Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Cadence Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,716	Closed	-$795K	–	655
2018 Q3	$795K	Sell	5,716 -988	-15%	-$124K	0.04%	433
2018 Q2	$832K	Buy	6,704 +82	+1%	+$9.58K	0.05%	419
2018 Q1	$738K	Buy	6,622 +620	+10%	+$74.1K	0.05%	438
2017 Q4	$718K	Buy	6,002 +1	+0%	+$122	0.05%	432
2017 Q3	$842K	Buy	+6,001	New	+$815K	0.05%	411
2015 Q1	–	Sell	-12,903	Closed	-$2.39M	–	664
2014 Q4	$2.39M	Sell	12,903 -5,940	-32%	-$1.1M	0.14%	200
2014 Q3	$3.13M	Sell	18,843 -11,157	-37%	-$1.83M	0.16%	166
2014 Q2	$4.69M	Buy	+30,000	New	+$4.74M	0.22%	149
2014 Q1	–	Sell	-34,939	Closed	-$4.64M	–	682
2013 Q4	$4.64M	Sell	34,939 -22,210	-39%	-$2.67M	0.18%	247
2013 Q3	$6.64M	Buy	57,149 +13,339	+30%	+$1.46M	0.23%	199
2013 Q2	$4.04M	Buy	+43,810	New	+$4.22M	0.19%	217

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cadence Capital Management's ALXN Position: Q4 2018 in Review

Cadence Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 5,716 shares — an estimated $795K sold.

Cadence Capital Management first reported a position in ALXN in Q2 2013 and held it in 11 quarters. The position peaked at $6.64M in Q3 2013. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Cadence Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Cadence Capital Management sold 5,716 Alexion Pharmaceuticals shares in Q4 2018, an estimated $795K.
Cadence Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Cadence Capital Management's Alexion Pharmaceuticals position peaked at $6.64M in Q3 2013.
609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Cadence Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.